Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

Joseph Contessa appointed chair of radiation oncology at Rutgers Cancer Institute

Joseph Contessa was named chair of radiation oncology for Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, and Rutgers New Jersey Medical School. He will also serve as associate director for translational research at Rutgers Cancer Institute.

August 08, 2025

Vol.51 No.31

Drugs & Targets

FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

FDA granted accelerated approval for Modeyso (dordaviprone) for the treatment of adult and pediatric patients (1 year of age and older) with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.

August 08, 2025

Vol.51 No.31

Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Drugs & Targets

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

FDA granted Breakthrough Therapy designation to elironrasib, a RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.

July 25, 2025

Vol.51 No.29

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

YOU MAY BE INTERESTED IN

Joseph Contessa appointed chair of radiation oncology at Rutgers Cancer Institute

FDA gives accelerated approval to Modeyso as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

Renew today!

Subscriber content

Never miss an issue!

Login